top of page
Dresden_web_banner_IMAGE.jpg

monday 10 March

12:00-12:45

Registration, Lunch & Posters

12:45-13:00

Presidential Welcome Address & Welcome of Organizer

​Frank Buchholz, Technical University Dresden & Zoltan Ivics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig

13:00-14:25 

Session 1: CRISPR Screens​

Chair: Boris Fehse, University of Hamburg

​

13:00-13:20  Michael BoutrosHeidelberg University

INV01: 

​​

13:20-13:40  John Fielden, ETH Zürich

INV02: Comprehensive Interrogation of Synthetic Lethality in the Human DNA Damage Response


13:40-13:55  Pratik Mallick, Technische Universität München

OR01: Establishment of a stable episomal replicon system for HBV to screen novel RNA-based antiviral gene therapies​

 

13:55-14:10  Sebastian ErkensWitten/Herdecke University

OR02: A direct comparison of the Sleeping Beauty Transposon system and the CRISPR/Cas9 machinery for genetic engineering​

 

14:10-14:25  Martina RubyCytiva

OR03: Using High-Throughput Genetic Screening to Improve Stable AAV Producer Cell Lines and to enhance viral vector production

14:25-14:45

Comfort Break

14:45-16:15 

Session 2: Delivery

​Chair: Sandy Tretbar, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig

​

14:45-15:05  Achim Aigner, University of Leipzig

INV03: Polymeric nanoparticles for RNA delivery: genome editing and beyond

​​

15:05-15:25  Ansgar Santel, Pantherna, Hennigsdorf

INV04: Beyond the Liver: Lipidnanoparticles (LNP) for Precise mRNA Delivery

​

15:25-15:45  Hildegard Büning, Hannover Medical School   

INV05 Capsid engineered AAV vectors as next generation in vivo delivery tools ​​

​

15:45-16:00  Paul ScholzAkribion Therapeutics

OR04 Programmable genome disruption enables selective elimination of cancer cells using a novel CRISPR-Cas nuclease​​

​

16:00-16:15  Jonas KathCharité University Medicine

OR05 ‘One-pot’ PASTA - Advanced T cell Engineering through Precise Integration of Super-Large Exogenous DNA

16:15-16:45

Coffee Break

16:45-18:10 

Session 3: Clinics

​Chair: Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig​

16:45-17:05  Jürgen Foell, Universitätsklinikum Regensburg

INV06: â€‹

 

17:05-17:25  Axel Schambach, Hannover Medical School 

INV07: Clinical translation of safer vectors and precision gene editing tools

 

17:25-17:40  Yulia SkokowaUniversity Hospital Tuebingen

OR06 Gene editing for pre-leukemia bone failure syndrome, severe congenital neutropenia, – current advances and critical considerations​

 

17:40-17:55  Tobias BexteGoethe University

OR07 CRISPR-edited allogeneic BCMA-CAR NK cells to overcome loss-of-target in multiple myeloma​

 

17:55-18:10  Ina LukschTechnische Universität München

OR08 AAV-mediated gene therapy in a porcine model of Duchenne Muscular Dystrophy

18:30-20:00 

Guided Tour of DHMD

20:00 

Dinner at Pulverturm an der Frauenkirche

An der Frauenkirche 12, 
01067 Dresden

Wedneday

TueSDAY 11 March

09:00-09:15

Registration & Welcome with coffee

09:15-09:50

Keynote

​Chair: Toni Cathomen, University of Freiburg

 

9:15-9:50  Kathleen Collins, Berkeley University

INV08: ​​Harnessing R2 retrotransposon machinery for site-specific safe-harbor transgene addition to the human genome​

09:50-11:25 

Session 4: Genome editing technologies

​Chair: Zoltan Ivics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig

​

09:50-10:10  Toni Cathomen, University of Freiburg

INV09: Safer Genome Editing: Innovations in Off-Target Management

​

10:10-10:30  Felix Lansing, Seamless Therapeutics, Dresden

INV10: ​Programmable recombinases to treat genetic diseases

​​​

10:30-10:50  Zoltan Ivics, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig

INV11: ​Advances in Sleeping Beauty transposon engineering of therapeutic cells

​​

10:50-11:10  Marc Güell, Pompeu Fabra University, Barcelona

INV12: ​Levering bioprospecting and generative AI to create new gene writers​​

​

11:10-11:25  Evangelia AnagnostouUniversity of Freiburg

OR09 An enhanced Single-Strand Break-Based Strategy for safer and more efficient Genome Editing

11:25-12:00

Coffee break & posters

12:00-13:30 

Session 5: Ethics

​​Chair: Frank Buchholz, Technical University Dresden

Moderator: Nadia PrimcUniversity of Heidelberg

​​​

12:20-12:40  Karla AlexUniversity of Heidelberg

INV13: The ethics of human genome editing

​​​

12:40-13:00  Klaus TannerUniversity of Heidelberg

INV14: 

​​

13:00–13:30 Panel discussion

13:30
Lunch and Posters

Thursday

Sekretariat der DG-GT e.V.
Institut für Experimentelle Hämatologie
Hildegard Büning
Carl-Neuberg-Str. 1
30625 Hannover

  • X
  • Facebook
  • LinkedIn
  • YouTube

© 2021 Die Deutsche Gesellschaft für Gentherapie e.V.

bottom of page